We aimed to evaluate the PD-L1 (CD274) expression using highly sensitive clone 73 − 10 and spatial transcriptomics (ST) analysis to elucidate the role of PD-L1 in HNSCC and thus potentially expand the pool of eligible patients. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.